Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions

Cardiovascular Diabetology

Review

Dong Yin¹  Kefei Dou¹  Jingyang Chen² 

[1] Cardiometabolic Medicine Center, Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037, Beijing, China;Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037, Beijing, China;

关键词: HbA1c;    Coronary heart disease;    T2DM;    Intensified glycemic control;    Curvilinear correlation;    HbA1c variability;    GLP-1 RA;    SGLT2i;    Haptoglobin phenotype;   

DOI  :  10.1186/s12933-023-01875-8

 received in 2023-04-17, accepted in 2023-06-02,  发布年份 2023

来源: Springer

【 摘 要 】

The occurrence and development of coronary heart disease (CHD) are closely linked to fluctuations in blood glucose levels. While the efficacy of intensified treatment guided by HbA1c levels remains uncertain for individuals with diabetes and CHD, this review summarizes the findings and conclusions regarding HbA1c in the context of CHD. Our review showed a curvilinear correlation between regulated level of HbA1c and therapeutic effectiveness of intensified glycemic control among patients with type 2 diabetes and coronary heart disease. It is necessary to optimize the dynamic monitoring indicators of HbA1c, combine genetic profiles, haptoglobin phenotypes for example and select more suitable hypoglycemic drugs to establish more appropriate glucose-controlling guideline for patients with CHD at different stage of diabetes.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 8